Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment

Biochemical Pharmacology

Volumn 71, Issue 1-2, 2005, Pages 50-60

  Muscella, Antonella ^a   Urso, Loredana ^a   Calabriso, Nadia ^b   Ciccarese, Antonella ^a   Migoni, Danilo ^a   Fanizzi, Francesco Paolo ^a   Di Jeso, Bruno ^a   Storelli, Carlo ^a   Marsigliante, Santo ^a  

^a UNIVERSITY OF SALENTO   (Italy)

^b Dipartimento di Ingegneria dell'Innovazione   (Italy)

Author keywords

Cisplatin; ERK; PC Cl3; PKB Akt; PKC

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; THYROID CELL; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TRANSFORMED; CISPLATIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; THYROID GLAND;

EID: 28244439312     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.10.022     Document Type: Article

References (47)

1. A. Eastman Activation of programmed cell death by anticancer agents: cisplatin as a model system Cancer Cells 2 1990 275 280
2. B. Koberle, J.R. Masters, J.A. Hartley, and R.D. Wood Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours Curr Biol 9 1999 273 276
3. X. Yang, F. Zheng, H. Xing, Q. Gao, W. Wei, and Y. Lu Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer J Cancer Res Clin Oncol 130 2004 423 428
4. Y. Shaul c-Abl, activation and nuclear targets Cell Death Differ 7 2000 10 16
5. W. Dempke, W. Voigt, A. Grothey, B.T. Hill, and H.J. Schmoll Cisplatin resistance and oncogenes - a review Anti-Cancer Drugs 11 2000 225 236
6. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
7. B. Brenner, U. Koppenhoefer, C. Weinstock, O. Linderkamp, F. Lang, and E. Gulbins Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153 J Biol Chem 272 1997 22173 22181
8. X. Wang, J.L. Martindale, Y. Liu, and N.J. Holbrook The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival Biochem J 333 1998 291 300
9. 2. Role in cell survival following oxidant injury J Biol Chem 271 1996 4138 4142
10. R. Aikawa, I. Komuro, T. Yamazaki, Y. Zou, S. Kudoh, and M. Tanaka Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats J Clin Invest 100 1997 1813 1821
11. Hayakawa, M. Ohmichi, H. Kurachi, H. Ikegami, A. Kimura, and T. Matsuoka Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line J Biol Chem 274 1999 31648 31654
12. D.L. Persons, E.M. Yazlovitskaya, W. Cui, and J.C. Pelling Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin Clin Cancer Res 5 1999 1007 1014
13. X.S. Gao, J. Asaumi, S. Kawasaki, K. Nishikawa, M. Kuroda, and Y. Takeda Sensitivity of anticancer drugs in NIH3T3 cells transfected with oncogenes accompanied by pSV2neo vector Anticancer Res 15 1995 1911 1914
14. T. Fokstuen, Y.B. Rabo, J.N. Zhou, J. Karlson, A. Platz, and M.C. Shoshan The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line Anticancer Res 17 1997 2347 2352
15. G. Wallin, G. Lundell, and J. Tennvall Anaplastic giant cell thyroid carcinoma Scand J Surg 93 2004 272 277
16. W. Voigt, A. Bulankin, T. Muller, C. Schoeber, A. Grothey, and C. Hoang-Vu Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines Clin Cancer Res 6 2000 2087 2093
17. A. Fusco, M.T. Berlingieri, P.P. Di Fiore, G. Portella, M. Grieco, and G. Vecchio One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes Mol Cell Biol 7 1987 3365 3370
18. M.T. Berlingieri, M. Santoro, C. Battaglia, M. Grieco, and A. Fusco The adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes Oncogene 8 1993 249 255
19. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytoxity assay J Immunol Methods 65 1993 55 63
20. +ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells J Endocrinol 173 2002 315 323
21. D.R. Alessi, A. Cuenda, P. Cohen, DT. Dudley, and A.R. Saltiel PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo J Biol Chem 270 1995 27489 27494
22. +ATPase activity through a pathway involving PKC-zeta in rat thyroid cells J Physiol 546 2003 461 470
23. G. Martiny-Baron, M.G. Kazanietz, H. Mischak, P.M. Blumberg, G. Kochs, and H. Hug Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976 J Biol Chem 268 1993 9194 9197
24. M.L. Standaert, L. Galloway, P. Karnam, G. Bandyopadhyay, J. Moscat, and R.V. Farese Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport J Biol Chem 272 1997 30075 30082
25. M.P. Sajan, M.L. Standaert, G. Bandyopadhyay, M.J. Quon, T.R. Burke, and R.V. Farese PKC- and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes J Biol Chem 274 1999 30495 30500
26. K. Merienne, S. Jacquot, M. Zeniou, S. Pannetier, P. Sassone-Corsi, and A. Hanauer Activation of RSK by UV-light: phosphorylation dynamics and involvement of the MAPK pathway Oncogene 19 2000 4221 4229
27. T. Wang, Y.C. Hu, S. Dong, M. Fan, D. Tamae, and M. Ozeki Co-activation of ERK, NF-kappaB, and GADD45beta in response to ionizing radiation J Biol Chem 280 2005 12593 12601
28. W. Cui, E.M. Yazlovitskaya, M.S. Mayo, J.C. Pellings, and E.L. Persons Cisplatin-induced response of c-jun N terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines Mol Carcinog 29 2000 219 228
29. D.L. Persons, E.M. Yazlovitskaya, and J.C. Pelling Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin J Biol Chem 275 2000 35778 35785
30. X. Wang, J.L. Martindale, and N.J. Holbrook Requirement for ERK activation in cisplatin-induced apoptosis J Biol Chem 275 2000 39435 39443
31. J.F. Sweeney, P.K. Nguyen, G. Omann, and D.B. Hinshaw Granulocyte-macrophage colony-stimulating factor rescues human polymorphonuclear leukocytes from ultraviolet irradiation-accelerated apoptosis J Surg Res 81 1999 108 112
32. D. Upadhyay, V. Panduri, and D.W. Kamp Fibroblast growth factor-10 prevents asbestos-induced alveolar epithelial cell apoptosis by a mitogen-activated protein kinase-dependent mechanism Am J Respir Cell Mol Biol 32 2005 232 238
33. A. Mandic, K. Viktorsson, T. Heiden, J. Hansson, and M.C. Shoshan The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis Melanoma Res 11 2001 11 19
34. P.Y. Yeh, S.E. Chuang, K.H. Yeh, Y.C. Song, C.K. Ea, and A.L. Cheng Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF-κB activation Biochem Pharmacol 63 2002 1423 1430
35. M.G. Elia, A. Muscella, S. Romano, S. Greco, B. Di Jeso, and T. Verri Effects of extracellular nucleotides in the thyroid: P2Y2 receptor-mediated ERK1/2 activation and c-Fos induction in PC-Cl3 cells Cell Signal 17 2005 739 749
36. L. Smith, L. Chen, M.E. Reyland, T.A. DeVries, R.V. Talanian, and S. Omura Activation of atypical protein kinase C zeta by caspase processing and degradation by the ubiquitin-proteasome system J Biol Chem 275 2000 40620 40627
37. C. Bezombes, A. de Thonel, A. Apostolou, T. Louat, J.P. Jaffrezou, and G. Laurent Overexpression of protein kinase C zeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation Mol Pharmacol 62 2002 1446 1455
38. M.T. Diaz-Meco, J. Lozano, M.M. Municio, E. Berra, S. Frutos, and L. Sanz Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta J Biol Chem 269 1994 31706 31710
39. M.W. Wooten, M.L. Seibenhener, L.H. Matthews, G. Zhou, and E.S. Coleman Modulation of zeta-protein kinase C by cyclic AMP in PC12 cells occurs through phosphorylation by protein kinase A J Neurochem 67 1996 1023 1031
40. D.C. Schonwasser, R.M. Marais, C.J. Marshall, and P.J. Parker Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes Mol Cell Biol 18 1998 790 798
41. S.L. Sutor, B.T. Vroman, E.A. Armstrong, R.T. Abraham, and L.M. Karnitz A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf J Biol Chem 274 1999 7002 7010
42. T.R. King, Y. Fang, E.S. Mahon, and D.H. Anderson Using a phage display library to identify basic residues in A-Raf required to mediate binding to the Src homology 2 domains of the p85 subunit of phosphatidylinositol 3′-kinase J Biol Chem 275 2000 36450 36456
43. D.R. Alessi, M.T. Kozlowski, W.Q.P. Weng, N. Morrice, and J. Avruch 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro Curr Biol 8 1997 69 81
44. K. Datta, A. Bellacosa, T.O. Chan, and P.N. Tsichlis Akt is a direct target of the phosphatidylinositol 3-kinase J Biol Chem 271 1996 30835 30839
45. V. Gagnon, I. Mathieu, E. Sexton, K. Leblanc, and E. Asselin AKT involvement in cisplatin chemoresistance of human uterine cancer cells Gynecol Oncol 94 2004 785 795
46. J.G. Viniegra, J.H. Losa, V.J. Sanchez-Arevalo, C. Parada Cobo, V.M. Soria, and Y. Ramon Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin Oncogene 10 2002 7131 7136
47. J. Hayakawa, M. Ohmichi, H. Kurachi, Y. Kanda, K. Hisamoto, and Y. Nishio Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin Cancer Res 60 2002 5988 5994